written on 10.03.2014
pt:
Tags:
,

Novartis orphan drug Jakavi nabs 'blockbuster' forecasts on new data

TAGS: ,

Novartis may have another cancer blockbuster on its hands. New Phase III data on Jakavi (ruxolitinib) has Wall Street analysts predicting that it will easily pass the $1 billion mark.

Latest Report